The headline in brief
- In July 2026 the FDA gave Novartis’ Fabhalta (iptacopan) a full traditional approval to slow kidney-function decline in adults with primary IgA nephropathy, upgrading the accelerated approval it already held.
- The upgrade rests on the phase 3 APPLAUSE-IgAN trial: over two years, kidney function slipped about 48% slower on the drug than on placebo.
- It is the first and only complement inhibitor cleared for this use, and it is a daily oral pill, not an infusion.
Two kinds of yes
The FDA can say yes in two registers. The tentative version is accelerated approval: a drug clears on an early surrogate signal, with the company on the hook to come back and prove the outcome that actually matters. Fabhalta went through that door first, on its power to cut protein leaking into the urine. In July it earned the firmer yes, a full traditional approval, because the long-term outcome data finally landed.
For someone living with IgA nephropathy (IgAN), that distinction is the whole story. In IgAN, deposits of the antibody IgA clog the kidney’s filters and scar them slowly, and untreated it walks a lot of patients toward dialysis or a transplant over years. Nobody doubted iptacopan could move a lab value. The open question was whether it keeps kidneys filtering. APPLAUSE-IgAN says it does.
What the phase 3 numbers say
APPLAUSE-IgAN was built to settle that: randomized, double-blind, placebo-controlled, and run long enough to watch eGFR, the standard read on how well kidneys filter. Across 24 months, patients on iptacopan lost filtering capacity roughly 48% slower than the placebo group. In slope terms that is about 3.02 mL/min/1.73m2 per year of eGFR preserved. Over a disease that plays out across decades, banking that much function each year compounds.
The proteinuria drop that won the earlier accelerated nod still hangs together as the mechanism check, about a 44% fall from baseline against 9% on placebo. Protein in the urine both marks kidney damage and drives more of it, so cutting the protein and slowing the decline are two readings of the same effect.
| Drug and route | Fabhalta (iptacopan), Novartis, oral daily pill |
| How it works | Blocks factor B in the alternative complement pathway |
| Pivotal trial | APPLAUSE-IgAN, phase 3, double-blind, placebo-controlled |
| Kidney decline vs placebo | ~48% slower over 24 months (eGFR slope diff ~3.02 mL/min/1.73m2/yr) |
| Proteinuria (earlier interim) | ~44% off baseline vs ~9% on placebo |
| Common adverse reactions | Abdominal pain, dizziness, nausea |
| Status | Full FDA approval, July 2026, up from accelerated |
Why aim at complement, and why a pill matters
Standard IgAN care leans on blood-pressure drugs and, lately, broad immune suppression. Iptacopan is deliberately narrower. It shuts down factor B, a piece of the alternative complement pathway that runs unchecked in IgAN and keeps the kidney inflamed. Hit that one arm and the goal is to quiet the damage without flattening the whole immune system.
The oral part is not a footnote. A daily pill asks less of a patient than a clinic infusion, and that usually widens both who starts a drug and who stays on it.
What the upgrade actually shifts
An accelerated approval carries a quiet asterisk. Payers can be cautious, and some clinicians hold off until the confirmatory data show up. Traditional approval pulls that asterisk off, and it tends to loosen both prescribing confidence and insurance coverage. This is the moment where real-world uptake can broaden.
None of that makes it a cure, and it is not for every IgAN patient. The label targets adults at risk of progression. The common side effects, abdominal pain, dizziness, and nausea, are manageable but real, and the long-run safety picture will keep filling in as more people take it outside a trial. What changed in July is the weight of evidence behind the drug, and for a slow, unforgiving kidney disease, that weight is exactly what nephrologists had been waiting on.
Sources:
- Novartis media release, “Fabhalta receives FDA traditional approval in primary IgAN”
- Healio Nephrology, “Fabhalta gains full FDA approval in IgA nephropathy”
- Renal & Urology News, “Fabhalta Earns Full FDA Approval to Slow Kidney Decline in Primary IgAN”
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.